{"organizations": [], "uuid": "fa877511a733f9c864b0b2f4433bed5a6ca74cce", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180511.html", "section_title": "Archive News &amp; Video for Friday, 11 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kitov-announces-consensi-commercia/brief-kitov-announces-consensi-commercialization-agreement-for-china-idUSFWN1SI15Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Kitov Announces Consensi Commercialization Agreement For China", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.709, "site_type": "news", "published": "2018-05-11T20:35:00.000+03:00", "replies_count": 0, "uuid": "fa877511a733f9c864b0b2f4433bed5a6ca74cce"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kitov-announces-consensi-commercia/brief-kitov-announces-consensi-commercialization-agreement-for-china-idUSFWN1SI15Z", "ord_in_thread": 0, "title": "BRIEF-Kitov Announces Consensi Commercialization Agreement For China", "locations": [], "entities": {"persons": [{"name": "kitov", "sentiment": "negative"}, {"name": "changshan", "sentiment": "none"}], "locations": [{"name": "china", "sentiment": "none"}, {"name": "china", "sentiment": "none"}, {"name": "consensi", "sentiment": "none"}], "organizations": [{"name": "kitov pharma ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "changshan pharma", "sentiment": "none"}, {"name": "u.s. fda", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 11 (Reuters) - Kitov Pharma Ltd:\n* KITOV ANNOUNCES CONSENSIâ„¢ COMMERCIALIZATION AGREEMENT FOR CHINA\n* KITOV PHARMA LTD - KITOV IS ENTITLED TO RECEIVE UP TO OF $3.5 MILLION FOR U.S. FDA APPROVAL OF CONSENSI, WHICH HAS A PDUFA DATE OF MAY 31\n* KITOV PHARMA LTD - RECEIVVAL UP TO OF $3.5 MILLION FOR U.S. FDA APPROVAL OF CONSENSI AND ALSO FOR CHINA REGULATORY MILESTONES\n* KITOV PHARMA - UPON RECEIPT OF MARKETING AUTHORIZATION IN CHINA, CHANGSHAN PHARMA WILL HAVE EXCLUSIVE RIGHT & LICENSE TO IMPORT SELL CONSENSI IN CHINA\n* KITOV PHARMA LTD - CHANGSHAN PHARMA WILL BE RESPONSIBLE FOR FINANCING AND SEEKING REGULATORY APPROVAL FOR CONSENSI IN CHINA\n* KITOV PHARMA LTD - KITOV IS ENTITLED TO RECEIVE UP TO AN OF $6.0 MILLION FOR PREDEFINED COMMERCIAL MILESTONES\n* KITOV PHARMA LTD - KITOV IS ALSO ENTITLED TO RECEIVE UP TO 12% ROYALTIES ON NET SALES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-11T20:35:00.000+03:00", "crawled": "2018-05-12T17:33:23.069+03:00", "highlightTitle": ""}